The first of it's kind in the US.
Researchers at the Mayo Clinic of Rochester, MN have developed a blood test that can detect the future risk of adverse cardiovascular events in patients with developing coronary atery disease.
The blood test measures plasma ceramides. These are "waxy, lipid molecules that have been associated with cardiovascular disease."
The test will be useful for patients who already have CAD and treatment is not improving and younger patients with premature CAD.
It is only for specific cases such as patients who have progressing coronary artery disease. The test may also be useful in patients who are at risk according to the risk calculator from the American College of Cardiology/American Heart Association. It can also aid in treatment options and their progression.
"The ceramides are promising biomarkers for prediction of adverse CV events in primary and secondary prevention."
The risk assessed by the plasma ceramides is independent of other established biomarkers and there are indications that high ceramide concentrations can be modified by common lipid-lowering therapies according to Dr. Jaffe.
Safe and efective ozone therapies are beneficial in better heart health.
Healthy Heart Ozone Chelation Therapy